Mats Merup

3.2k total citations
59 papers, 2.2k citations indexed

About

Mats Merup is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Mats Merup has authored 59 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Genetics, 21 papers in Pathology and Forensic Medicine and 21 papers in Hematology. Recurrent topics in Mats Merup's work include Chronic Lymphocytic Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (19 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). Mats Merup is often cited by papers focused on Chronic Lymphocytic Leukemia Research (28 papers), Lymphoma Diagnosis and Treatment (19 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). Mats Merup collaborates with scholars based in Sweden, Denmark and Finland. Mats Merup's co-authors include Gunnar Juliusson, Gösta Gahrton, Christer Sundström, Stefan Einhorn, Dan Grandér, Omid Rasool, Gerard Tobin, Richard Rosenquist, Ulf Thunberg and Jan Samuelsson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Mats Merup

59 papers receiving 2.1k citations

Peers

Mats Merup
Debra M. Lillington United Kingdom
Anja Mottok Germany
Holger Nückel Germany
Christine Dierks Germany
Ellen D. McPhail United States
Nathalie Gachard France
Benjamin S. Braun United States
Inga Vater Germany
L Bergui Italy
James D. Phelan United States
Debra M. Lillington United Kingdom
Mats Merup
Citations per year, relative to Mats Merup Mats Merup (= 1×) peers Debra M. Lillington

Countries citing papers authored by Mats Merup

Since Specialization
Citations

This map shows the geographic impact of Mats Merup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mats Merup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mats Merup more than expected).

Fields of papers citing papers by Mats Merup

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mats Merup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mats Merup. The network helps show where Mats Merup may publish in the future.

Co-authorship network of co-authors of Mats Merup

This figure shows the co-authorship network connecting the top 25 collaborators of Mats Merup. A scholar is included among the top collaborators of Mats Merup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mats Merup. Mats Merup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
d’Amore, Francesco, Thomas Relander, Grete F. Lauritzsen, et al.. (2012). Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. Journal of Clinical Oncology. 30(25). 3093–3099. 386 indexed citations
2.
d’Amore, Francesco, Thomas Relander, Grete F. Lauritzsen, et al.. (2012). Upfront Autologuos Stem Cell Transplantation in Peripheral T-cell Lymphoma (NLG-T-01). 1 indexed citations
3.
Merup, Mats, Gunnar Birgegård, Lorentz Brinch, et al.. (2011). The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplantation. 47(3). 380–386. 43 indexed citations
4.
d’Amore, Francesco, Thomas Relander, Esa Jantunen, et al.. (2009). Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral t-cell lymphomas (PTCLS) - overall and subtype-specific results of a phase II study from the nordic lymphoma group. Lund University Publications (Lund University). 20 indexed citations
5.
Mansouri, Mahmoud, Anna Åleskog, Mikael Jondal, et al.. (2009). IGHV3‐21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia. European Journal Of Haematology. 84(2). 109–116. 9 indexed citations
6.
Nahi, Hareth, Sören Lehmann, Sofia Bengtzén, et al.. (2008). Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leukemia & lymphoma. 49(3). 508–516. 26 indexed citations
7.
Palmblad, Jan, Magnus Björkholm, Jack Kutti, et al.. (2008). TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. International Journal of Medical Sciences. 5(2). 87–91. 6 indexed citations
8.
Pellagatti, Andrea, Martin Jädersten, Ann‐Mari Forsblom, et al.. (2007). Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients. Proceedings of the National Academy of Sciences. 104(27). 11406–11411. 170 indexed citations
9.
Samuelsson, Jan, Hans Carl Hasselbalch, Øystein Bruserud, et al.. (2006). A phase II trial of pegylated interferon α‐2b therapy for polycythemia vera and essential thrombocythemia. Cancer. 106(11). 2397–2405. 78 indexed citations
10.
Fält, Susann, Mats Merup, Gösta Gahrton, Bo Lambert, & Anders Wennborg. (2005). Identification of progression markers in B-CLL by gene expression profiling. Experimental Hematology. 33(8). 883–893. 33 indexed citations
11.
Tobin, Gerard, Ulf Thunberg, Amy E. Knight Johnson, et al.. (2002). V(a)3-21 gene utilizing chronic lymphocytic leukemias display restricted V lambda 2-14 gene usage and homologous CDR3s.. Blood. 100(11). 362. 4 indexed citations
12.
13.
Lundin, Jeanette, Eva Kimby, Magnus Björkholm, et al.. (2001). Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).. Blood. 98. 4 indexed citations
14.
Wu, Xiushan, Mats Merup, Monika Jansson, et al.. (1999). Molecular Analysis of the Human Chromosome 5q13.3 Region in Patients with Hairy Cell Leukemia and Identification of Tumor Suppressor Gene Candidates. Genomics. 60(2). 161–171. 25 indexed citations
15.
Merup, Mats, Gunnar Juliusson, Xiushan Wu, et al.. (1997). Amplification of multiple regions of chromosome 12, including 12q13–15, in chronic lymphocytic leukaemia. European Journal Of Haematology. 58(3). 174–180. 38 indexed citations
16.
Heyman, Mats, Yie Liu, Dan Grandér, et al.. (1997). Inverse correlation between loss of heterozygosity of the short arm of chromosome 12 and p15ink4B/p16ink4 gene inactivation in childhood acute lymphoblastic leukaemia. British Journal of Haematology. 98(1). 147–150. 11 indexed citations
17.
Merup, Mats, Tatjana Spasokoukotskaja, Stefan Einhorn, et al.. (1996). Bcl‐2 rearrangements with breakpoints in both vcr and mbr in non‐Hodgkin’s lymphomas and chronic lymphocytic leukaemia. British Journal of Haematology. 92(3). 647–652. 24 indexed citations
18.
Merup, Mats, et al.. (1995). α‐2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. American Journal of Hematology. 48(3). 163–167. 10 indexed citations
19.
Merup, Mats, et al.. (1994). Interferon Antibodies in Thrombocythemia. Journal of Interferon Research. 14(4). 187–189. 4 indexed citations
20.
Merup, Mats, Gunnar Juliusson, Lennart Hammarström, Smith Rjh, & Gösta Gahrton. (1994). T‐cell receptor β gene rearrangements in leukaemic B‐cells from patients with chronic lymphocytic leukaemia: association with chromosome 6 deletions. British Journal of Haematology. 86(2). 291–297. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Debra M. Lillington Breakdown of academic impact, for papers by Anja Mottok Breakdown of academic impact, for papers by Holger Nückel Breakdown of academic impact, for papers by Christine Dierks Breakdown of academic impact, for papers by Ellen D. McPhail Breakdown of academic impact, for papers by Nathalie Gachard Breakdown of academic impact, for papers by Benjamin S. Braun Breakdown of academic impact, for papers by Inga Vater Breakdown of academic impact, for papers by L Bergui Breakdown of academic impact, for papers by James D. Phelan
Rankless by CCL
2026